Facilitated subcutaneous immunoglobulin (fSCIg) therapy - practical considerations

Clinical and Experimental Immunology

Volumn 182, Issue 3, 2015, Pages 302-313

  Ponsford, M ^a   Carne, E ^a   Kingdon, C ^a   Joyce, C ^a   Price, C ^a   Williams, C ^a   El Shanawany, T ^a   Williams, P ^a   Jolles, S ^a  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

Facilitated subcutaneous immunoglobulin (fSCIg); Hyaluronidase; Intravenous immunoglobulin (IVIg); Primary immunodeficiency (PID); Subcutaneous immunoglobulin (SCIg)

Indexed keywords

HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN;

ARTICLE; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG WITHDRAWAL; EXTRACELLULAR MATRIX; FATIGUE; HUMAN; IMMUNOTHERAPY; INFUSION PUMP; INFUSION RATE; OUTCOME ASSESSMENT; PATIENT DECISION MAKING; PATIENT INFORMATION; PERSONAL EXPERIENCE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; TRAINING; FEMALE; FOLLOW UP; IMMUNOLOGIC DEFICIENCY SYNDROMES; MALE; MEDICAL EDUCATION; SUBCUTANEOUS DRUG ADMINISTRATION;

EDUCATION, MEDICAL, CONTINUING; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULINS; IMMUNOLOGIC DEFICIENCY SYNDROMES; INJECTIONS, SUBCUTANEOUS; MALE;

EID: 84946479136     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12694     Document Type: Article

References (33)

1. Lucas M, Lee M, Lortan J, Lopez-Granados E, Misbah S, Chapel H. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol 2010; 125:1354-60.
2. Bruton OC. Agammaglobulinemia. Pediatrics 1952; 9:722-8.
3. Bruton OC. A decade with agammaglobulinemia. J Pediatr 1962; 60:672-6.
4. Jolles S, Orange JS, Gardulf A et al. Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease. Clin Exp Immunol 2015; 179:146-60.
5. Supersaxo A, Hein WR, Steffen H. Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm Res 1990; 7:167-9.
6. Laurent TC, Laurent UB, Fraser JR. The structure and function of hyaluronan: an overview. Immunol Cell Biol 1996; 74:A1-7.
7. Hechter O. Reconstitution of the dermal barrier to fluid diffusion following administration of hyaluronidase. Proc Soc Exp Biol Med 1948; 67:343.
8. Bookbinder LH, Hofer A, Haller MF et al. Recombinant human enzyme for enhanced interstitial transport of therapeutics. J Control Release 2006; 114:230-41.
9. Matarasso SL, Carruthers JD, Jewell ML, Restylane Consensus Group. Consensus recommendations for soft-tissue augmentation with nonanimal stabilized hyaluronic acid (Restylane). Plast Reconstr Surg 2006; 117 (Suppl. 3):3S-34S; discussion 5S-43S.
10. Krang DW, Jadin L, Nekoroski T, Drake FH, Zepeda ML. Recombinant human hyaluronidase PH20 (rHuPH20) facilitates subcutaneous infusions of large volumes of immunoglobulin in a swine model. Drug Deliv Transl Res 2012; 2:254-64.
11. Schwartzman J. Hyaluronidase; a review of its therapeutic use in pediatrics. J Pediatr 1951; 39:491-502.
12. Knight E, Carne E, Novak B et al. Self-administered hyaluronidase-facilitated subcutaneous immunoglobulin home therapy in a patient with primary immunodeficiency. J Clin Pathol 2010; 63:846-7.
13. Carne E, Ponsford M, El-Shanawany T, Williams P, Pickersgill T, Jolles S. Five years of self-administered hyaluronidase facilitated subcutaneous immunoglobulin (fSCIg) home therapy in a patient with primary immunodeficiency. J Clin Pathol 2015. Epub date 2015-07-19.
14. Szépfalusi Z, Nentwich I, Dobner M, Pillwein K, Urbanek R. IgE-mediated allergic reaction to hyaluronidase in paediatric oncological patients. Eur J Pediatr 1997; 156:199-203.
15. Agrawal A, McLure HA, Dabbs TR. Allergic reaction to hyaluronidase after a peribulbar injection. Anaesthesia 2003; 58:493-94.
16. Park S, Lim LT. Orbital inflammation secondary to a delayed hypersensitivity reaction to sub-Tenon's hyaluronidase. Semin Opthalmol 2014; 29:57-8.
17. Wasserman RL. Overview of recombinant human hyaluronidase-facilitated subcutaneous infusion of IgG in primary immunodeficiencies. Immunotherapy 2014; 6:553-67.
18. Wasserman RL, Melamed I, Stein MR et al. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. J Allergy Clin Immunol 2012; 130:951-7.
19. Baxter Healthcare Prescribing information for HyQvia [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] Solution for subcutaneous administration: Baxter Healthcare, Thetford, Norfolk, UK; 2014. Available at: http://www.baxter.com/downloads/healthcare_professionals/products/HYQVIA_PI.pdf (accessed 1 June 2015).
20. Lawo J-P, Hubsch A, Rojavin M, eds. Quantification of the wear-off effect towards the end of the intravenous immunoglobulin infusion interval: pooled data analysis. J Allergy Clin Immunol 2014; 133 (Suppl.):AB179S.
21. Brew JD, Dill LV. Rate of blood flow through standard gage needles under pressure. J Am Med Assoc 1949; 140:1145-7.
22. Gill HS, Prausnitz MR. Does needle size matter? J Diabetes Sci Technol 2007; 1:725-9.
23. Berger M. Subcutaneous administration of IgG. Immunol Allergy Clin North Am 2008; 28:779-802.
24. Nicolay U, Haag S, Eichmann F, Herget S, Spruck D, Gardulf A. Measuring treatment satisfaction in patients with primary immunodeficiency diseases receiving lifelong immunoglobulin replacement therapy. Qual Life Res 2005; 14:1683-91.
25. Gathmann B, Binder N, Ehl S Kindle G, ESID Registry Working Party. The European internet-based patient and research database for primary immunodeficiencies: update 2011. Clin Exp Immunol 2012; 167:479-91.
26. Cunningham-Rundles C. How I treat common variable immune deficiency. Blood 2010; 116:7-15.
27. Ducruet T, Levasseur M-C, Des Roches A, Kafal A, Dicaire R, Haddad E. Pharmacoeconomic advantages of subcutaneous versus intravenous immunoglobulin treatment in a Canadian pediatric center. J Allergy Clin Immunol 2012; 131:585-7, e1-3.
28. Gardulf A, Andersen V, Björkander J et al. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet 1995; 345:365-9.
29. Berger M, Jolles S, Orange JS, Sleasman JW. Bioavailability of IgG administered by the subcutaneous route. J Clin Immunol 2013; 33:984-90.
30. Ochs HD, Gupta S, Kiessling P, Nicolay U, Berger M. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol 2006; 26:265-73.
31. Jolles S, Bernatowska E, de Gracia J et al. Efficacy and safety of Hizentra in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy. Clin Immunol 2011; 141:90-102.
32. Ewart HE, Qualie M, O'Shaughnessy D. Commissioning immunoglobulin: advice to commissioners and commissioning bodies, 2nd edn. Leeds: NHS England, 2011 (updated 2011; accessed 10 April 2015).
33. Jolles S, Stein MR, Longhurst HJ et al. New frontiers in subcutaneous immunoglobulin treatment. Biol Ther 2011; 1:3.